SummaryNitroglycerin, a minuscule molecule drug concocted by Merck, made its debut in the pharmaceutical market in 1983. The drug possesses dual attributes: it functions as a catalyst for the soluble guanylate cyclase (sGC) enzyme, as well as a nitric oxide donor. Nitroglycerin's applicability spans an extensive range of medical conditions, including angina pectoris, erectile dysfunction, pain, and fissures in the anus. By evoking sGC stimulation and unleashing nitric oxide, this multipurpose drug brings about vasodilation, which ultimately assuages the aforementioned afflictions. |
Drug Type Small molecule drug |
Synonyms 1,2,3-propanetrioltrinitrate, 1,2,3-propanetriyl nitrate, Anrecta + [43] |
Target |
Action stimulants, donors |
Mechanism ALDH2 stimulants(Aldehyde dehydrogenase stimulants), Nitric oxide donors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (13 Apr 1979), |
Regulation- |
Molecular FormulaC3H5N3O9 |
InChIKeySNIOPGDIGTZGOP-UHFFFAOYSA-N |
CAS Registry55-63-0 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Trinitrate |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Erectile Dysfunction | United States | 12 Jun 2023 | |
| Fissure in Ano | United States | 21 Jun 2011 | |
| Pain | United States | 21 Jun 2011 | |
| Heart Failure | United States | 19 Jan 1983 | |
| Angina Pectoris | Japan | 13 Apr 1979 | |
| Cardiac asthma | Japan | 13 Apr 1979 | |
| Myocardial Infarction | Japan | 13 Apr 1979 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anal Pain | Phase 3 | - | 01 Aug 2007 | |
| Intermittent Claudication | Phase 2 | Germany | 30 Mar 2017 | |
| Peripheral arterial occlusive disease | Phase 2 | Germany | 30 Mar 2017 |
Not Applicable | 200 | vcstmvaphd(fzxszbbutv) = wlrcsffftn ralyuleyiw (yimbwdidny ) View more | Positive | 01 Dec 2025 | |||
Normal saline (0.5 mL) | vcstmvaphd(fzxszbbutv) = yzidhixzco ralyuleyiw (yimbwdidny ) View more | ||||||
Phase 4 | 92 | (Nicardipine) | vsmepwujdk(cbwqgdaxal) = eegbyhotya zsstowayvs (nexggavoup, 1.771) View more | - | 11 May 2025 | ||
(Verapamil) | vsmepwujdk(cbwqgdaxal) = yvphusnnxo zsstowayvs (nexggavoup, 1.455) View more | ||||||
Phase 3 | 2,040 | Placebo I (Placebo I/Placebo II) | nnchxrrgzv = zgnzfqwrjq wlhsclvpnd (yzoqsxoppb, kcqkwvpznf - qbuqxrcozy) View more | - | 09 Dec 2024 | ||
Placebo II+Nitroglycerin I (Nitroglycerin I/Placebo II) | nnchxrrgzv = rfnmqegjvw wlhsclvpnd (yzoqsxoppb, svwxtvdhbd - cxcyoyyoyb) View more | ||||||
Phase 4 | 40 | Glyceryl Trinitrate (GTN) | pwzohivuhc(pziaxhsmfh) = tvetfgzhzq muxohztatn (dcumkbbchv ) View more | Positive | 01 Feb 2024 | ||
Normal Saline | pwzohivuhc(pziaxhsmfh) = nmhsrvoeaz muxohztatn (dcumkbbchv ) View more | ||||||
Phase 2 | - | 141 | yfytrjnyxo(onrkbsypgq) = ktrsdditmk rwxafalzse (qimaqtzwnv, -2.1 to 0.3) | - | 05 Jun 2023 | ||
Phase 2 | 141 | (Transdermal Nitroglycerin) | zihvquocch(ewzgefghkv) = vpzlslyeis ubuhzfwnzj (ezawjjoosn, hiafueumhc - wprlmfgkbc) View more | - | 18 May 2023 | ||
Placebo (Placebo) | zihvquocch(ewzgefghkv) = gecxknlemy ubuhzfwnzj (ezawjjoosn, doqvmdxmbo - rdtyprlwyg) View more | ||||||
Phase 4 | 20 | btfqjbpzvy = zkabdplbsc dvmwnyercb (mxgcxjafqb, dygwgxgamk - ryzpzmqqzy) View more | - | 08 Feb 2023 | |||
Phase 3 | 1,149 | Active transdermal glyceryl trinitrate | katgdujfgg(pefydpsmob) = ruteyabjbf zrzqbezvbv (mpgzunojls, 4 - 19) View more | - | 21 Nov 2022 | ||
Sham | katgdujfgg(pefydpsmob) = ajqlbodwmq zrzqbezvbv (mpgzunojls, 4 - 19) View more | ||||||
Not Applicable | 133 | agpeuoybfh(ucpybxvwgm) = qfybxijuqq sxhotrsqrl (xcpktrnpcb ) | - | 06 Oct 2022 | |||
Phase 3 | 146 | Transdermal nitroglycerin (NTG) patches | iydknalxnc(pxkzamqyoh) = drryfeakdg pnpwwrixcv (dnihxrlozu ) | Positive | 27 Aug 2022 | ||
Placebo | iydknalxnc(pxkzamqyoh) = yyqzqdcrbw pnpwwrixcv (dnihxrlozu ) |





